Nurse Practitioner · Indiana, PA
NPI
1376089334
Since 2017
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1265 Wayne Ave Ste 103
Indiana, PA, 15701
Phone (724) 463-1048
Groups this clinician bills Medicare through
Medicare paid, 2024
$40K
3,819 services
Medicare patients, 2024
242
Average age 72
Drug cost, 2024
$4.2M
9,314 prescriptions
Company payments, 2025
$44K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Annette Kubalek was code 99214 (office e&m - established), 250 times for 171 patients. In total Annette Kubalek billed 3,819 services in 16 codes, and Medicare paid $40K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-11-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 250 | 171 | $73.81 | $18K |
| 95251 Test - Miscellaneous | Office | 102 | 63 | $21.34 | $2,176 |
| 99213 Office E&M - Established | Office | 39 | 36 | $47.65 | $1,858 |
| 99204 Office E&M - New | Office | 26 | 26 | $107.25 | $2,789 |
| 99203 Office E&M - New | Office | 19 | 19 | $63.95 | $1,215 |
By year: 2022 $25K for 430 services; 2023 $25K for 420 services; 2024 $40K for 3,819 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 22 | 21 | $9.52 | $209 |
Medicare prescription drug claims, 2024
In 2024, the drug Annette Kubalek prescribed most often to Medicare patients was Ozempic (Semaglutide), with 780 prescriptions and refills. In total Annette Kubalek wrote 9,314 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 780 | 948 | 155 | $877K |
| Levothyroxine Sodium Generic | 670 | 1,213 | 158 | $5,937 |
| Trulicity Dulaglutide | 425 | 502 | 96 | $464K |
| Jardiance Empagliflozin | 367 | 549 | 77 | $308K |
| Atorvastatin Calcium Generic | 360 | 919 | 103 | $4,781 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 311 | 498 | 87 | $38K |
| Metformin Hcl Er Metformin Hcl | 303 | 594 | 81 | $4,892 |
| Metformin Hcl Generic | 288 | 630 | 72 | $2,378 |
| Rosuvastatin Calcium Generic | 258 | 634 | 79 | $7,396 |
| Xultophy 100-3.6 Insulin Degludec/Liraglutide | 251 | 313 | 54 | $371K |
| Mounjaro Tirzepatide | 240 | 246 | 54 | $248K |
| Farxiga Dapagliflozin Propanediol | 218 | 302 | 44 | $165K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 191 | 227 | 41 | $117K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 187 | 474 | 74 | $18K |
| Glipizide Er Glipizide | 177 | 428 | 56 | $2,585 |
Brand drugs: 5,088 claims; generic drugs: 3,523 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Annette Kubalek $44K ($44K in general payments such as food, travel and fees) from 19 companies. The largest payer was Abbott Laboratories with $43K.
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories ABT | 222 | $43K |
| Tandem Diabetes Care, Inc. TNDM | 13 | $197 |
| Amgen Inc. AMGN | 4 | $81.67 |
| Medtronic, Inc. MDT | 4 | $78.55 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $67.8 |
| Lilly USA, LLC LLY | 3 | $61.35 |
| Mannkind Corporation MNKD | 1 | $45.89 |
| Averitas Pharma Inc. | 2 | $44.24 |
| Novo Nordisk Inc NVO | 2 | $43.04 |
| CeQur Corporation | 1 | $42.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.